Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses

BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren’t yet approved or economically inaccessible. Howev...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Radiat Oncol
Main Authors: Ni, Jianjiao, Li, Guodong, Yang, Xi, Chu, Li, Wang, Jialei, Li, Yida, Zou, Liqing, Li, Yuan, Xie, Congying, Zhu, Zhengfei
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6417092/
https://ncbi.nlm.nih.gov/pubmed/30866974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13014-019-1240-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki